Skip to main content
. Author manuscript; available in PMC: 2013 Dec 3.
Published in final edited form as: Neuroscience. 2011 Mar 31;183:221–229. doi: 10.1016/j.neuroscience.2011.03.052

Figure 4. Analgesic efficacy of deltorphin II in bone cancer pain and inflammatory pain.

Figure 4

A graph of the effective dose of deltorphin II (ED50) inducing 50% relief of the mechanical allodynia and hypersensitivity was obtained from the data presented in Fig. 2B and 3B at the corresponding peak responses (i.e., 15 min after i.t. injection of deltorphin II). No difference was observed between cancer (ED50=10.1 μg) and CFA-treated rats (ED50=17.6 μg) (Statistical analysis was determined using two-way ANOVA followed by Bonferroni’s post test).